The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a presentation from the symposium by Gail J. Roboz, Weill Cornell Medicine, New York, US, in which she discussed the management of patients with acute myeloid leukemia (AML) with FLT3-internal tandem duplication (ITD) and FLT3-tyrosine kinase domain (TKD) mutations in clinical practice.

Roboz reflected on whether 7+3 regimens are the most appropriate approach for older patients with FLT3-mutated AML, and reviewed considerations for using targeted FLT3 inhibitor therapies in combination with standard intensive chemotherapy. She then highlighted the importance of measurable residual disease (MRD) assessment in guiding treatment decisions before and after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the potential of triplet therapies for the treatment of patients with FLT3m AML.

This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.